INTEGRA LIFESCIENCES HOLDINGS CORP 8-K

What Happened
Integra LifeSciences Holdings Corporation issued a press release on July 29, 2026 (attached as Exhibit 99.1 to the Form 8-K) announcing its financial results for the quarter ended June 30, 2026. The release includes reconciliations from GAAP to several non‑GAAP measures and provides forward-looking guidance for organic revenues and adjusted earnings per diluted share. The Form 8-K was signed by Lea Knight, Executive Vice President and Chief Financial Officer, on July 29, 2026.

Key Details

• Press release dated July 29, 2026 reporting results for the quarter ended June 30, 2026 (Exhibit 99.1).
• Reconciliations included: GAAP revenues to organic revenues; GAAP net income to adjusted EBITDA; GAAP net income to adjusted net income; GAAP gross profit/margin to adjusted gross profit/margin; GAAP EPS to adjusted EPS — all for the quarters ended June 30, 2026 and 2025.
• Also reconciled GAAP total debt to net debt for June 30, 2026 and December 31, 2025.
• Management provided forward-looking guidance for organic revenues and adjusted EPS but did not provide reconciliations to the most directly comparable forward‑looking GAAP measures, citing inability to reasonably estimate certain GAAP expense items and foreign exchange impacts.

Why It Matters
The 8‑K informs investors that Integra is reporting quarterly financial results and providing a set of non‑GAAP metrics (organic revenue, adjusted EBITDA, adjusted EPS, etc.) that management is using to describe performance and guide expectations. Because the company did not reconcile its forward-looking guidance to GAAP figures—due to variability in certain costs and currency effects—investors should rely on the provided reconciliations for historical context and watch for the company’s upcoming periodic filings (e.g., Form 10-Q) or analyst updates for full GAAP details.